Participant flow

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor · Source last updated 2020-10-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.

   id

   FG000

   title

   Imatinib Mesylate

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         63

      type

      STARTED

   2. achievements

      1. comment

         Subjects contributing data to the primary analysis are considered to have completed the study.

         group Id

         FG000

         num Subjects

         52

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice